Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

被引：0
|
作者：
Lucia Del Mastro
Alessandra Fabi
Mauro Mansutti
Michele De Laurentiis
Antonio Durando
Domenico Franco Merlo
Paolo Bruzzi
Ignazia La Torre
Matteo Ceccarelli
Gbenga Kazeem
Paolo Marchi
Davide Boy
Marco Venturini
Sabino De Placido
Francesco Cognetti
机构：
[1] UO Sviluppo Terapie Innovative,IRCCS AOU San Martino
[2] Regina Elena Institute, IST
[3] S. Maria della Misericordia Hospital, National Institute for Cancer Research
[4] University of Naples Federico II,Division Oncology
[5] National Cancer Institute “Fondazione Pascale”,Department Oncology
[6] A.O.O.I. Regina Margherita S. Anna,Department of Endocrinology and Molecular and Clinical Oncology
[7] UO Epidemiologia Clinica,Department of Senology, Division of Breast Oncology
[8] Medical Department,IRCCS AOU San Martino
[9] Eli Lilly UK, IST
[10] S. Cuore – Don Calabria Hospital, National Institute for Cancer Research
来源：
BMC Cancer | / 13卷
关键词：
Metastatic breast cancer; Weekly schedule; 3-weekly schedule;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
    Del Mastro, Lucia
    Fabi, Alessandra
    Mansutti, Mauro
    De Laurentiis, Michele
    Durando, Antonio
    Merlo, Domenico Franco
    Bruzzi, Paolo
    La Torre, Ignazia
    Ceccarelli, Matteo
    Kazeem, Gbenga
    Marchi, Paolo
    Boy, Davide
    Venturini, Marco
    De Placido, Sabino
    Cognetti, Francesco
    BMC CANCER, 2013, 13
  • [2] Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment.
    Del Mastro, Lucia
    Fabi, Alessandra
    Mansutti, Mauro
    De Laurentiis, Michele
    Durando, Antonio
    Colantuoni, Giuseppe
    Zaniboni, Alberto
    Barni, Sandro
    Merlo, Domenico Franco
    Bruzzi, Paolo
    La Torre, Ignazia
    Ceccarelli, Matteo
    Kazeem, Gbenga
    Marchi, Paolo
    Boy, Davide
    Venturini, Marco
    De Placido, Sabino
    Cognetti, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
    Hu, Xi-Chun
    Zhang, Jian
    Xu, Bing-He
    Cai, Li
    Ragaz, Joseph
    Wang, Zhong-Hua
    Wang, Bi-Yun
    Teng, Yue-E
    Tong, Zhong-Sheng
    Pan, Yue-Yin
    Yin, Yong-Mei
    Wu, Chang-Ping
    Jiang, Ze-Fei
    Wang, Xiao-Jia
    Lou, Gu-Yin
    Liu, Dong-Geng
    Feng, Ji-Feng
    Luo, Jian-Feng
    Sun, Kang
    Gu, Ya-Jia
    Wu, Jiong
    Shao, Zhi-Min
    LANCET ONCOLOGY, 2015, 16 (04): : 436 - 446
  • [4] A COMPARISON OF FIRST-LINE TREATMENT WITH GEMCITABINE PLUS DOCETAXEL VERSUS GEMCITABINE PLUS VINORELBINE IN WOMEN WITH METASTATIC BREAST CANCER
    Bensalem, A.
    Bouzid, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [5] Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Tije, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den Bosch, J.
    Kroep, J. R.
    Braun, J. J.
    van Tinteren, H.
    Boven, E.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3077 - 3088
  • [6] Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer
    Sánchez-Rovira, P
    Jaén, A
    González, E
    Porras, I
    Dueñas, R
    Medina, B
    Mohedano, N
    Fernández, M
    Martos, M
    Lozano, A
    Carrasco, E
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 44 - 47
  • [7] Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium
    Lorusso, V
    Crucitta, E
    Silvestris, N
    Rosati, G
    Manzione, L
    De Lena, M
    ONCOLOGY REPORTS, 2005, 13 (02) : 283 - 287
  • [8] Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
    Zhou, T.
    Yang, Y.
    Ma, S.
    Lin, L.
    Zhou, T.
    Zhang, C.
    Ding, X.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    Huang, Y.
    Zhang, L.
    ESMO OPEN, 2021, 6 (06)
  • [9] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
  • [10] Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.
    Guardino, A. E.
    Chen, M.
    Levy, M.
    Chen, M.
    CANCER RESEARCH, 2009, 69 (24) : 853S - 853S
12345